An earnings report released ahead of the opening bell on Friday noted that revenue rose 7% to HUF 857.5 billion.
The cost of sales fell 6% to HUF 266.8 bln, boosting gross profit 13% to HUF 590.7 bln.
The bottom line was also lifted by a HUF 12.9 bln net financial gain, after a HUF 24 bln loss in the base period.
Earnings per share came to HUF 1,307.
Richter noted that all of its business segments posted double-digit sales growth, helped in part by the positive impact of foreign exchange rates. Sales of Vraylar, the brand name of Richter’s antipsychotic cariprazine, rose 18% to HUF 229 bln.
Richter noted that AbbVie, its U.S. partner, expects Vraylar sales to reach around USD 3.5 bln in 2025.
In guidance for 2025, Richter put its pharmaceutical sales at EUR 2.3 bln-2.4 bln, at constant exchange rates, up around 10%.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
